Blog
116 Articles
Positive Results For Borderline Resectable Disease Pilot Study
Dr. Zev Wainberg provides details on a trial of chemotherapy and immunotherapy for patients with borderline resectable pancreatic cancer.
mRNA Vaccine Trial Expands to Numerous Locations
The mRNA vaccine trial spearheaded by Dr. Vinod Balachandran has opened in more locations in the US and around the world.
Can SBRT Become More Effective?
Radiation oncologist Dr. Todd Aguilera is looking for ways to make SBRT a more effective treatment for pancreatic cancer.
Using Ultrasound to Enhance the Effectiveness of Chemotherapy
A clinical trial combines ultrasound with a microbubble contrast agent to make chemotherapy more effective.
Slowing the Growth of One Type of Advanced Neuroendocrine Tumor
Dr. Kelsey Klute explains the advantages of the radiopharmaceutical lutetium Lu 177 dotatate treatment for certain neuroendocrine tumors.
Leveraging Nanoparticle Technology for Paclitaxel Delivery in Pancreatic Cancer Patients
Dr. Allyson Ocean explains why nanoparticle delivery technology for getting paclitaxel to the tumor could be advantageous for patients.
For Families at Risk, Remote Education May Be Key in Improving Genetic Testing Uptake
What’s the best way to educate families at risk for pancreatic cancer about genetic testing? Dr. Sapna Syngal discusses the results of the GENERATE study.
Platform Trial Increases Efficiency in Studying Immunotherapy
Dr. Elizabeth Jaffee is betting that three types of immunotherapy will rev up the immune system and make chemotherapy more effective in a platform trial.
Chemotherapy Plus Immunotherapy Trial Shows Promise
Dr. Gulam Manji leads a clinical trial that uses two types of immunotherapy to enhance chemotherapy for pancreatic cancer patients.
New FDA Approval Brings More Treatment Options in Metastatic Disease
The FDA has approved the use of liposomal irinotecan in the chemotherapy combination NALIRIFOX for metastatic pancreatic cancer.
New Vaccine Harnesses Power Of the Lymph Nodes
A promising new vaccine targets KRAS, the most common mutation in pancreatic cancer. Dr. Shubham Pant provides an update.
Steely Strength to Keep Going
Long-term survivor Davi D’Agostino discovered she carries the BRCA2 mutation, which changed her treatment plan to targeted therapy.
Treating High Blood Sugar in People With Pancreatic Cancer
A new clinical trial explores the effectiveness of the drug glipizide in controlling high blood sugar in pancreatic cancer patients.
Two-Drug Combo Targets KRAS and Fights Resistance
Researcher Hervé Tiriac leads a clinical trial for a new drug combination targeting KRAS and chemotherapy resistance.
A New Approach to Immunotherapy for Advanced Pancreatic Cancer
Will a new type of immunotherapy help prevent tumors from developing resistance to chemotherapy? Research is underway.